Incidence of Adverse Psychiatric Events During Treatment of Inflammatory Bowel Disease With Biologic Therapies: A Systematic Review. Issue 1 (19th December 2019)

• Record Type: Journal Article
• Authors: Jain, Avni; Marrie, Ruth Ann; Shafer, Leigh Anne; Graff, Lesley A; Patten, Scott B; El-Gabalawy, Renée; Sareen, Jitender; Bolton, James M; Fisk, John D; Bernstein, Charles N
• Is Part Of: Crohn's & colitis 360. Volume 2:Issue 1(2020)
• Publication Date: 2019-12-19
• Subjects: adverse psychiatric events -- meta-analysis -- randomized controlled trials -- biologic therapy; Crohn's disease -- Periodicals; Colitis -- Periodicals; 616.344
• DOI: 10.1093/crocol/otz053
• Languages: English
• ISSNs: 2631-827X

Abstract

Abstract: We conducted a systematic review and a fixed-effects meta-analysis to determine whether incident adverse psychiatric events (APE) including depression, anxiety, psychosis, or suicide were associated with biologic therapy in IBD. Six randomized controlled trials and a cohort study met criteria, reporting an incidence of APE in 4, 882 patients. The risk difference per 100 person-months of any APE with a biologic medication was 0.01 (95% confidence interval = 0.00–0.02). There was insufficient evidence available in randomized controlled trials to conclude that biologic therapy in IBD is associated with an increased incidence of APE. Lay Summary: We conducted a systematic review to determine whether adverse psychiatric events (APE) were associated with biologic therapy in IBD. In the seven studies, meeting search criteria biologic therapy in IBD was not associated with an increased incidence of APE.